LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50
LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.
Stocks · News reference
B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41
B of A Securities analyst Jason Gerberry initiates coverage on Apnimed (NASDAQ:APMD) with a Buy rating and announces Price Target of $41.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.
Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating
Evercore ISI Group analyst Umer Raffat initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating.